Jonathan Tunnicliffe - Revance Board Member
| RVNC Stock | USD 3.79 0.03 0.80% |
Executive
Mr. Jonathan Tunnicliffe is a Board Member of Revance Therapeutics Inc. He is currently a Partner of NovaQuest Capital Management L.L.C. an investment firm that focuses on the biopharmaceutical sector a position he has held since November 2010. From 2000 until 2010 he was global head of due diligence for the NQ business unit of Quintiles Transnational a contract research company. Mr. Tunnicliffe was previously a founding member and Director of Operations of a specialized clinical research organization SCubed Inc. In Mr. Tunnicliffes earlier career he was a medical statistician at SmithKline and French and at the University of Sheffield since 2011.
| Age | 49 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Address | 1222 Demonbreun Street, Nashville, TN, United States, 37203 |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Revance Management Efficiency
The company has return on total asset (ROA) of (0.2602) % which means that it has lost $0.2602 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.24, whereas Return On Tangible Assets are forecasted to decline to (0.73). At present, Revance's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 11.7 M, whereas Total Assets are forecasted to decline to about 331.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer Larson | Deciphera Pharmaceuticals LLC | N/A | |
| John Slebir | Dynavax Technologies | N/A | |
| Greg Martini | Ironwood Pharmaceuticals | N/A | |
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Kevin Brodbeck | Deciphera Pharmaceuticals LLC | N/A | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| David Boyer | Neurocrine Biosciences | 44 | |
| Daniel Martin | Deciphera Pharmaceuticals LLC | 49 | |
| Lisa Price | Deciphera Pharmaceuticals LLC | N/A | |
| Matthew Abernethy | Neurocrine Biosciences | 44 | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
| Valentin MD | Eagle Pharmaceuticals | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
| Christopher Morl | Deciphera Pharmaceuticals LLC | 59 | |
| Peter Norman | Alkermes Plc | N/A | |
| Dong Yu | Dynavax Technologies | N/A | |
Management Performance
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.26 |
Revance Leadership Team
Elected by the shareholders, the Revance's board of directors comprises two types of representatives: Revance inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance's management team and ensure that shareholders' interests are well served. Revance's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Putman, Vice President - Digital | ||
| Cyril Allouche, Principal Financial Officer and Principal Accounting Officer | ||
| Caryn McDowell, Senior Vice President General Counsel, and Corporate Secretary | ||
| Phyllis Gardner, Board Member | ||
| Jonathan Tunnicliffe, Board Member | ||
| Lauren Silvernail, CFO, Executive Vice President of Corporate Development | ||
| Jill Beraud, Director | ||
| Sharon Hall, Vice President of Regulatory Affairs | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Philip Vickers, Independent Director | ||
| Dan Browne, Co-Founder and Presidentident, CEO, Board Member | ||
| Julian Gangolli, Director | ||
| Abhay Joshi, COO | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Robert Byrnes, Independent Director | ||
| Ron Wooten, Independent Director | ||
| Jim Glasheen, Board Member | ||
| Jessica Serra, Head ESG | ||
| Ronald Eastman, Board Member | ||
| Aubrey Rankin, Consultant | ||
| Phil Vickers, Director | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Todd Zavodnick, Chief Commercial Officer and President Aesthetics & Therapeutics | ||
| Erica Bazerkanian, Vice President of Marketing | ||
| Ronald Wooten, Independent Director | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Azita Nejad, VP Operations | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Daniel Browne, Co-Founder and Presidentident, CEO, Director | ||
| Marc Korenberg, Senior Director - Commercial Operations | ||
| Curtis Ruegg, Executive VP of RandD and Technical Operations | ||
| Angus Russell, Chairman of the Board | ||
| Mark Prygocki, Director | ||
| Chris Nolet, Director | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.38) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 558.85 M | ||||
| Shares Outstanding | 104.22 M | ||||
| Shares Owned By Insiders | 8.47 % | ||||
| Shares Owned By Institutions | 76.19 % | ||||
| Number Of Shares Shorted | 13.55 M | ||||
| Price To Earning | (7.60) X |
Currently Active Assets on Macroaxis
When determining whether Revance offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Revance's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Revance Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Revance Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revance. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Revance Stock analysis
When running Revance's price analysis, check to measure Revance's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revance is operating at the current time. Most of Revance's value examination focuses on studying past and present price action to predict the probability of Revance's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revance's price. Additionally, you may evaluate how the addition of Revance to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Revance's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.83) | Revenue Per Share 2.766 | Quarterly Revenue Growth 0.398 | Return On Assets (0.26) | Return On Equity (20.97) |
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.